Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) (FASTR)
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) - FASTR Trial
Sponsor: Reprieve Cardiovascular, Inc
Listed as NCT05174312, this NA trial focuses on Acute Decompensated Heart Failure and remains completed. Sponsored by Reprieve Cardiovascular, Inc, it has been updated 11 times since 2022, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Aug 2025 — Sep 2025 [monthly]
Completed NA
-
Apr 2025 — Aug 2025 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Dec 2024 — Apr 2025 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
Aug 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jul 2024 — Aug 2024 [monthly]
Recruiting NA
-
Mar 2024 — Jul 2024 [monthly]
Recruiting NA
-
Jan 2024 — Mar 2024 [monthly]
Recruiting NA
-
Dec 2022 — Jan 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2022 — Dec 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Reprieve Cardiovascular, Inc
For direct contact, visit the study record on ClinicalTrials.gov .